HIV-1 infection has been transformed by combined anti-retroviral therapy (ART), changing a universally fatal infection into a controllable infection. However, major obstacles for an HIV-1 cure exist. The HIV latent reservoir, which exists in resting CD4+ T cells, is not impacted by ART, and can reactivate when ART is interrupted or ceased. Additionally, multi-drug resistance can arise. One alternate approach to conventional HIV-1 drug treatment that is being explored involves gene therapies utilizing RNA-directed gene regulation. Commonly known as RNA interference (RNAi), short interfering RNA (siRNA) induce gene silencing in conserved biological pathways, which require a high degree of sequence specificity. This review will provide an overview of the silencing pathways, the current RNAi technologies being developed for HIV-1 gene therapy, current clinical trials, and the challenges faced in progressing these treatments into clinical trials.
CITATION STYLE
Klemm, V., Mitchell, J., Cortez-Jugo, C., Cavalieri, F., Symonds, G., Caruso, F., … Ahlenstiel, C. (2016, December 7). Achieving HIV-1 control through RNA-directed gene regulation. Genes. MDPI AG. https://doi.org/10.3390/genes7120119
Mendeley helps you to discover research relevant for your work.